Dr. Carl Rosenkrantz, MD Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 5352 Linton Blvd, Delray Beach, FL 33484 Phone: 561-498-4440 |
Lorna Sohn Williams, MD Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 16129 Bristol Pointe Dr, Delray Beach, FL 33446 Phone: 561-638-6266 |
Dr. Stephen Joel Leighton, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 5352 Linton Blvd, Delray Beach, FL 33484 Phone: 561-498-4440 |
Mr. Timothy R. Williams, M.D. Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 5280 Linton Blvd, Delray Beach, FL 33484 Phone: 561-323-6498 Fax: 561-584-7775 |
Dr. Craig H Thame, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 5352 Linton Blvd, Attn: Radiology Dept, Delray Beach, FL 33484 Phone: 561-498-4440 |
Mark Anderson Culton, M.D. Radiology - Diagnostic Radiology Medicare: Medicare Enrolled Practice Location: 7254 Clunie Pl Apt 15004, Delray Beach, FL 33446 Phone: 408-656-0850 |
Dr. Mark S Rosenberg, MD Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 5352 Linton Blvd, Delray Beach, FL 33484 Phone: 561-498-4440 |
News Archive
A new study published in the journal Nature Communications in February 2020 shows that secretions from stem cells in the lung can be utilized to nebulize injured lungs due to several types of lung fibrosis in rats and mice. This could well result in the development of less invasive and more effective therapies for lung fibrosis.
Since 2006, several published studies have associated the use of some acid suppression medications in hospitalized high-risk babies with infections, necrotizing enterocolitis and increased risk of death. Those medications - histamine-2 receptor antagonists, such as ranitidine (Zantac and others), and proton pump inhibitors, such as esomeprazole (Nexium and others) - were originally approved by the U.S. Food and Drug Administration for use in adults and older children.
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
MicroStockProfit.com announces an investment report featuring CombinatoRx Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 6 days ago